Publication:
Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta

Simple item page
dc.contributor.coauthorEtzion, Ohad
dc.contributor.coauthorHamid, Saeed Sadiq
dc.contributor.coauthorAsselah, Tarik
dc.contributor.coauthorGherlan, George Sebastian
dc.contributor.coauthorTurcanu, Adela
dc.contributor.coauthorPetrivna, Tsarynna
dc.contributor.coauthorWeissfeld, Lisa
dc.contributor.coauthorChoong, Ingrid
dc.contributor.coauthorHislop, Colin
dc.contributor.coauthorApelian, David
dc.contributor.coauthorButi, Maria
dc.contributor.coauthorGheorghe, Liana
dc.contributor.coauthorIliescu, Elena Laura
dc.contributor.coauthorVoronkova, Natalia
dc.contributor.coauthorBarsukova, Natalia
dc.contributor.coauthorAleman, Soo
dc.contributor.coauthorFeld, Jordan J.
dc.contributor.coauthorReau, Nancy S.
dc.contributor.coauthorBrunetto, Maurizia
dc.contributor.coauthorLampertico, Pietro
dc.contributor.coauthorHeller, Theo
dc.contributor.coauthorKoh, Chris
dc.contributor.coauthorGlenn, Jeffrey
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorYurdaydın, Cihan
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-12-29T09:38:31Z
dc.date.issued2023
dc.description.indexedbyWOS
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume78
dc.identifier.eissn1600-0641
dc.identifier.issn0168-8278
dc.identifier.quartileQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22697
dc.identifier.wos1037135100013
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofJournal of Hepatology
dc.subjectGastroenterology and hepatology
dc.titleWeek 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
dc.typeMeeting Abstract
dspace.entity.typePublication
local.contributor.kuauthorYurdaydın, Cihan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Collections

Publications without Fulltext